AngioDynamics (ANGO) Q4 2025: MedTech Revenue Jumps 22% as Platform Transformation Accelerates
AngioDynamics’ MedTech-led transformation delivered outsized Q4 growth, with platform adoption and margin resilience despite new tariffs. Mechanical thrombectomy and Ariane platform traction signal sustainable gains, while operational discipline and reimbursement tailwinds set up fiscal 2026 for further margin and cash flow improvement.
Summary
- MedTech Portfolio Drives Expansion: Mechanical thrombectomy and Ariane platforms captured share in high-growth markets.
- Margin Resilience Amid Tariff Headwinds: Operational efficiency offset tariff impact, maintaining profitability trajectory.
- Reimbursement and Regulatory Milestones: NanoKnife and AlphaVac catalysts position AngioDynamics for accelerated adoption in 2026.
Performance Analysis
AngioDynamics posted 12.7% revenue growth in Q4, with MedTech segment revenue up 22%, now representing 45% of total sales. Platform momentum was led by the Ariane atherectomy system, which delivered its sixteenth consecutive quarter of double-digit growth and now stands as the third largest product in its segment. Mechanical thrombectomy, including AngioVac and AlphaVac, surged 44.7%, reflecting differentiated technology and effective commercialization.
Gross margin held at 52.7% despite $1.6 million in new tariff costs, which hit MedTech disproportionately but were largely offset by manufacturing efficiency gains. Adjusted EBITDA turned positive, and free cash flow exceeded $16 million, underscoring effective cost controls. NanoKnife revenue was flat year-over-year, with probe sales up but capital sales down as expected; prostate procedures now constitute a record 81% of NanoKnife volume, a key mix improvement.
- MedTech Share Expansion: Segment now 45% of revenue, up from 41% last year, highlighting portfolio shift.
- Mechanical Thrombectomy Acceleration: AngioVac and AlphaVac combined growth outpaced the broader portfolio.
- Margin Protection: Tariff impact absorbed through operational leverage and cost actions.
Overall, the quarter validated AngioDynamics’ pivot to high-growth, high-margin MedTech platforms, with durable share gains and improved profitability despite external cost pressure.
Executive Commentary
"Our performance in the quarter and throughout fiscal 2025 validates that strategy and reflects our ability to drive execution. As this is our fiscal year-end call, I wanted to take the opportunity to highlight the progress we have made operationally this year as we have achieved great things here at AngioDynamics over the past 12 to 24 months, including key regulatory approvals, international market expansion, new product introductions, clinical data development, and critical reimbursement wins, among others, all of which have set us up to deliver profitable growth moving forward."
Jim Clemmer, President and Chief Executive Officer
"In the fourth quarter of FY25, we incurred $1.6 million of tariff expense, with more than half of that cost associated with our MedTech segment. This $1.6 million is included in our cost of goods sold and does impact gross margins and ultimately our EBITDA and EPS results. Given this dynamic, we're particularly pleased with our results and our ability to drive accelerated profitability despite this headwind."
Steve Trowbridge, Executive Vice President and Chief Financial Officer
Strategic Positioning
1. MedTech Platform Penetration
AngioDynamics’ MedTech platforms—Ariane, mechanical thrombectomy, and NanoKnife—are now the engine of growth, with MedTech revenue nearly doubling as a percentage of total company sales over five years. Ariane, a peripheral atherectomy platform, has surpassed $185 million in cumulative sales and is gaining share in both U.S. hospitals and new European markets post-CE mark. Mechanical thrombectomy, led by AngioVac and AlphaVac, is the fastest growing sub-segment, with new FDA and CE clearances fueling adoption.
2. Regulatory and Reimbursement Leverage
Regulatory wins and reimbursement milestones are unlocking new addressable markets. NanoKnife’s expanded prostate indication and CPT Category 1 codes for prostate and liver ablation, effective January 2026, position the business for a step-change in adoption. Similarly, the AlphaVac blood return version is advancing toward FDA clearance, aiming to further differentiate the thrombectomy suite and meet evolving customer expectations.
3. Operational Efficiency and Cost Structure
Manufacturing transition and cost optimization programs are driving sustainable margin improvement. Despite $1.6 million in Q4 tariff expense, AngioDynamics maintained margin expansion and expects $15 million in annualized cost savings by fiscal 2027. R&D investment remains at roughly 10% of sales, balancing innovation with disciplined SG&A and manufacturing spend.
4. Portfolio Focus and Capital Allocation
Management signaled no near-term appetite for major acquisitions or divestitures, citing confidence in the current portfolio’s growth runway. The company’s new $25 million revolver remains untapped, providing liquidity flexibility without diluting focus on existing platforms and clinical programs.
5. International Expansion
Early traction in Europe for Ariane following CE mark approval demonstrates the scalability of the commercial model. While the U.S. remains the primary growth driver, international sales are expected to be a meaningful, though smaller, contributor as awareness and regulatory access build.
Key Considerations
Q4 results reflect a company executing on a multi-year transformation to a MedTech-first model, with strong operational discipline and growing platform adoption. Investors should weigh the following:
Key Considerations:
- Platform Adoption Curve: Ariane and mechanical thrombectomy platforms are winning share against larger incumbents, supported by clinical evidence and sales force expansion.
- Tariff Volatility: New tariffs are an ongoing cost headwind, but mitigation efforts and pricing power have limited bottom-line erosion.
- NanoKnife Reimbursement Tailwind: Upcoming CPT-1 codes and growing urologist adoption set up a potential inflection in procedure volume and recurring disposable revenue.
- Cost Optimization Execution: Manufacturing transition is delivering early savings, with full benefits expected by fiscal 2027, supporting margin resilience.
- Balanced Capital Strategy: Prudent credit facility use and no near-term M&A or divestiture plans keep management focused on organic growth and operational leverage.
Risks
Tariff unpredictability remains a material risk, with management estimating a $4 to $6 million headwind for fiscal 2026 that could shift if trade policy evolves. Adoption of new platforms depends on continued clinical validation, reimbursement uptake, and competitive response. Any delays in regulatory pathways (e.g., AlphaVac blood return) or reimbursement rollout for NanoKnife could temper growth expectations. Macro volatility in hospital capital spending and international market access also warrant close monitoring.
Forward Outlook
For Q1 2026, AngioDynamics anticipates:
- Highest cash use of the year, approximately $20 million, before returning to cash generation in subsequent quarters
- Sequential growth in MedTech platforms, led by thrombectomy and Ariane
For full-year 2026, management guided:
- Net sales of $305 to $310 million (4% to 6% growth)
- MedTech sales up 12% to 15%, MedDevice flat
- Gross margin of 53.5% to 55.5%, including $4 to $6 million in tariffs
- Adjusted EBITDA of $3 to $8 million, positive full-year cash flow
Management emphasized continued MedTech share gains, margin protection, and cash generation as top priorities, with NanoKnife reimbursement and AlphaVac regulatory progress as key catalysts for H2 2026 acceleration.
- Monitor tariff developments and mitigation updates
- Track NanoKnife adoption as reimbursement takes effect
Takeaways
AngioDynamics’ Q4 and full-year results reinforce the durability of its MedTech transformation, with platform adoption, clinical validation, and operational discipline underpinning a positive outlook despite macro and policy headwinds.
- MedTech Momentum: Ariane and thrombectomy platforms are driving sustainable growth and margin mix improvement, with further upside from international expansion and new indications.
- Cost and Margin Management: Early manufacturing transition benefits and SG&A discipline are offsetting external cost shocks, supporting profitability even as tariffs rise.
- 2026 Watchpoints: Reimbursement-driven NanoKnife ramp, AlphaVac blood return clearance, and tariff mitigation will define the next stage of AngioDynamics’ earnings power.
Conclusion
AngioDynamics enters fiscal 2026 with clear momentum, a more resilient business model, and multiple platform growth levers. Execution on reimbursement and regulatory milestones, combined with disciplined cost management, will be critical to sustaining the company’s positive trajectory in a volatile market environment.
Industry Read-Through
AngioDynamics’ Q4 results highlight the power of focused MedTech portfolios, clinical differentiation, and reimbursement strategy in driving share gains against larger incumbents. Tariff volatility and cost structure discipline are sector-wide imperatives, with operational flexibility and supply chain agility now table stakes for MedTech peers. Reimbursement-driven inflection points (as with NanoKnife) are a key theme for oncology and interventional device companies, while the success of platform-based commercialization models is increasingly relevant across medical technology verticals.